Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET

Company Participants

Paul Little - Chief Financial Officer

David-Alexandre Gros - Chief Executive Officer

Steve Perrin - President and Chief Scientific Officer

Conference Call Participants

Pete Stavropoulos - Cantor Fitzgerald

Thomas Smith - SVB Securities

Rami Katkhuda - LifeSci Capital

Vernon Bernardino - H.C. Wainwright

Raymond Wu - Ladenburg Thalmann

Operator

Good afternoon, ladies and gentlemen and welcome to Eledon Pharmaceuticals first quarter 2023 earnings conference call. At this time, all lines are listen-only mode. [Operator Instructions] This call is being recorded on Thursday, May 11, 2023.

I would now like to turn the conference over to your host, Paul Little, CFO. Please go ahead.

Paul Little

Good afternoon, everyone, and thank you for joining Eledon's first quarter 2023 operating and financial results conference call. I am joined today on today's call by David-Alexandre Gros, Chief Executive Officer, and Steve Perrin, our President and Chief Scientific Officer. Jeff Bornstein, our Chief Medical Officer, is traveling today.

Earlier today, Eledon issued a press release announcing financial results for the first quarter ended March 31, 2023. You may access the release under the Investors tab on our company's website at eledon.com.

I would like to remind everyone that statements made during this conference call relating to Eledon's expected future performance, future business prospects, or future events or plans may include forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be subject to the Safe Harbor protection provided by the Reform Act. Actual outcomes and results could differ materially from these forecasts due to the impact of many factors beyond the control of Eledon.

Eledon expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events, or otherwise. Participants are directed to the risk factors set forth in Eledon's reports filed with the US Securities and Exchange Commission.

Now it is my pleasure to pass the call to Eledon’s CEO, Dr. David-Alexandre Gros. DA?

David-Alexandre Gros

Thank you, Paul, and thank you all for joining us today. We began the year by announcing our primary organizational focus on our kidney transplantation program, and have since directed our resources and efforts to advance this program forward. We believe that Tegoprubart, our anti-CD40 ligand antibody, can address a significant unmet need in patients undergoing kidney transplants through its potential to prevent rejection, maintain high graft function, and reduce the many toxicities associated with calcineurin inhibitors or CNIs. We believe there is a profound urgency for new treatment options to benefit patients receiving solid organ transplants and kidneys in particular.